Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (241-250 of 426) with videos related to

Pageof 43
Sort By:
The Prostate|March 28, 2024
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancerKate L Mahon, Sarah Im Sutherland, Hui Ming Lin, et al.
The New England Journal of Medicine|June 26, 2009
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersPeter C Fong, David S Boss, Timothy A Yap, et al.
The Lancet. Oncology|December 29, 2009
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyDavid Olmos, Sophie Postel-Vinay, L Rhoda Molife, et al.
European Urology Oncology|June 19, 2018
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate CancersPasquale Rescigno, David Lorente, David Dolling, et al.
British Journal of Cancer|March 6, 2008
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumoursS P Blagden, L R Molife, A Seebaran, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumorsDebashis Sarker, Rhoda Molife, T R Jeffrey Evans, et al.
Clinical and Translational Science|February 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid TumorsJatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher, et al.
Oncogene|July 26, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variantStephen J Pettitt, Nan Shao, Diana Zatreanu, et al.
Molecular Cancer Research : MCR|March 18, 2022
Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate CancersPamela J Maxwell, Melanie McKechnie, Christopher W Armstrong, et al.
Pageof 43

Showing results (241-250 of 426) with videos related to

Sort By:
Pageof 43
The Prostate|March 28, 2024
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancerKate L Mahon, Sarah Im Sutherland, Hui Ming Lin, et al.
The New England Journal of Medicine|June 26, 2009
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersPeter C Fong, David S Boss, Timothy A Yap, et al.
The Lancet. Oncology|December 29, 2009
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyDavid Olmos, Sophie Postel-Vinay, L Rhoda Molife, et al.
European Urology Oncology|June 19, 2018
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate CancersPasquale Rescigno, David Lorente, David Dolling, et al.
British Journal of Cancer|March 6, 2008
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumoursS P Blagden, L R Molife, A Seebaran, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumorsDebashis Sarker, Rhoda Molife, T R Jeffrey Evans, et al.
Clinical and Translational Science|February 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid TumorsJatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher, et al.
Oncogene|July 26, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variantStephen J Pettitt, Nan Shao, Diana Zatreanu, et al.
Molecular Cancer Research : MCR|March 18, 2022
Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate CancersPamela J Maxwell, Melanie McKechnie, Christopher W Armstrong, et al.
Pageof 43